174 related articles for article (PubMed ID: 25485499)
1. Proteasome inhibitors suppress the protein expression of mutant p53.
Halasi M; Pandit B; Gartel AL
Cell Cycle; 2014; 13(20):3202-6. PubMed ID: 25485499
[TBL] [Abstract][Full Text] [Related]
2. Arsenic trioxide reactivates proteasome-dependent degradation of mutant p53 protein in cancer cells in part via enhanced expression of Pirh2 E3 ligase.
Yan W; Jung YS; Zhang Y; Chen X
PLoS One; 2014; 9(8):e103497. PubMed ID: 25116336
[TBL] [Abstract][Full Text] [Related]
3. MDM2-mediated Inhibitory Effect of Arsenic Trioxide on Small Cell Lung Cancer Cell Line by Degrading Mutant p53.
Wang YS; Yin JZ; Shi XQ; Zhao XW; Li B; Yang MH
Anticancer Agents Med Chem; 2023; 23(16):1829-1837. PubMed ID: 37259217
[TBL] [Abstract][Full Text] [Related]
4. Mutant p53 protein is targeted by arsenic for degradation and plays a role in arsenic-mediated growth suppression.
Yan W; Zhang Y; Zhang J; Liu S; Cho SJ; Chen X
J Biol Chem; 2011 May; 286(20):17478-86. PubMed ID: 21454520
[TBL] [Abstract][Full Text] [Related]
5. Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib.
Ooi MG; Hayden PJ; Kotoula V; McMillin DW; Charalambous E; Daskalaki E; Raje NS; Munshi NC; Chauhan D; Hideshima T; Buon L; Clynes M; O'Gorman P; Richardson PG; Mitsiades CS; Anderson KC; Mitsiades N
Clin Cancer Res; 2009 Dec; 15(23):7153-60. PubMed ID: 19934289
[TBL] [Abstract][Full Text] [Related]
6. Oligomerization conditions Mdm2-mediated efficient p53 polyubiquitylation but not its proteasomal degradation.
Hjerpe R; Aillet F; Lopitz-Otsoa F; Lang V; Torres-Ramos M; Farrás R; Hay RT; Rodríguez MS
Int J Biochem Cell Biol; 2010 May; 42(5):725-35. PubMed ID: 20080206
[TBL] [Abstract][Full Text] [Related]
7. Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo.
Koblish HK; Zhao S; Franks CF; Donatelli RR; Tominovich RM; LaFrance LV; Leonard KA; Gushue JM; Parks DJ; Calvo RR; Milkiewicz KL; Marugán JJ; Raboisson P; Cummings MD; Grasberger BL; Johnson DL; Lu T; Molloy CJ; Maroney AC
Mol Cancer Ther; 2006 Jan; 5(1):160-9. PubMed ID: 16432175
[TBL] [Abstract][Full Text] [Related]
8. hnRNP K: an HDM2 target and transcriptional coactivator of p53 in response to DNA damage.
Moumen A; Masterson P; O'Connor MJ; Jackson SP
Cell; 2005 Dec; 123(6):1065-78. PubMed ID: 16360036
[TBL] [Abstract][Full Text] [Related]
9. The oncoprotein SS18-SSX1 promotes p53 ubiquitination and degradation by enhancing HDM2 stability.
D'Arcy P; Maruwge W; Ryan BA; Brodin B
Mol Cancer Res; 2008 Jan; 6(1):127-38. PubMed ID: 18234968
[TBL] [Abstract][Full Text] [Related]
10. Crucial role of TSC-22 in preventing the proteasomal degradation of p53 in cervical cancer.
Yoon CH; Rho SB; Kim ST; Kho S; Park J; Jang IS; Woo S; Kim SS; Lee JH; Lee SH
PLoS One; 2012; 7(8):e42006. PubMed ID: 22870275
[TBL] [Abstract][Full Text] [Related]
11. Constitutive Activation of DNA Damage Checkpoint Signaling Contributes to Mutant p53 Accumulation via Modulation of p53 Ubiquitination.
Frum RA; Love IM; Damle PK; Mukhopadhyay ND; Palit Deb S; Deb S; Grossman SR
Mol Cancer Res; 2016 May; 14(5):423-36. PubMed ID: 26965143
[TBL] [Abstract][Full Text] [Related]
12. Requirement for HDM2 activity in the rapid degradation of p53 in neuroblastoma.
Isaacs JS; Saito S; Neckers LM
J Biol Chem; 2001 May; 276(21):18497-506. PubMed ID: 11279110
[TBL] [Abstract][Full Text] [Related]
13. Differentiation of Hdm2-mediated p53 ubiquitination and Hdm2 autoubiquitination activity by small molecular weight inhibitors.
Lai Z; Yang T; Kim YB; Sielecki TM; Diamond MA; Strack P; Rolfe M; Caligiuri M; Benfield PA; Auger KR; Copeland RA
Proc Natl Acad Sci U S A; 2002 Nov; 99(23):14734-9. PubMed ID: 12407176
[TBL] [Abstract][Full Text] [Related]
14. Selective inhibition of histone deacetylase 2 induces p53-dependent survivin downregulation through MDM2 proteasomal degradation.
Seo SK; Hwang CS; Choe TB; Hong SI; Yi JY; Hwang SG; Lee HG; Oh ST; Lee YH; Park IC
Oncotarget; 2015 Sep; 6(28):26528-40. PubMed ID: 25605253
[TBL] [Abstract][Full Text] [Related]
15. The overexpression of multidrug resistance-associated proteins and gankyrin contribute to arsenic trioxide resistance in liver and gastric cancer cells.
Chen X; Zhang M; Liu LX
Oncol Rep; 2009 Jul; 22(1):73-80. PubMed ID: 19513507
[TBL] [Abstract][Full Text] [Related]
16. MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity.
Saha MN; Jiang H; Jayakar J; Reece D; Branch DR; Chang H
Cancer Biol Ther; 2010 Jun; 9(11):936-44. PubMed ID: 20418664
[TBL] [Abstract][Full Text] [Related]
17. Cyclooxygenase inhibitors modulate the p53/HDM2 pathway and enhance chemotherapy-induced apoptosis in neuroblastoma.
Lau L; Hansford LM; Cheng LS; Hang M; Baruchel S; Kaplan DR; Irwin MS
Oncogene; 2007 Mar; 26(13):1920-31. PubMed ID: 16983334
[TBL] [Abstract][Full Text] [Related]
18. HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function.
Lau LM; Nugent JK; Zhao X; Irwin MS
Oncogene; 2008 Feb; 27(7):997-1003. PubMed ID: 17700533
[TBL] [Abstract][Full Text] [Related]
19. Proteasome inhibitor MG132 induces thyroid cancer cell apoptosis by modulating the activity of transcription factor FOXO3a.
Qiang W; Sui F; Ma J; Li X; Ren X; Shao Y; Liu J; Guan H; Shi B; Hou P
Endocrine; 2017 Apr; 56(1):98-108. PubMed ID: 28220348
[TBL] [Abstract][Full Text] [Related]
20. Hdm2 is regulated by K-Ras and mediates p53-independent functions in pancreatic cancer cells.
Sui X; Shin S; Zhang R; Firozi PF; Yang L; Abbruzzese JL; Reddy SA
Oncogene; 2009 Feb; 28(5):709-20. PubMed ID: 19029954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
